Janus Kinase Inhibitors: all 1,428 studies that test it
Page 15 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015KCompletedNCT01364974Phase 1
- A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT01263899Phase 2
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT01236638Phase 2
- A Study Of Tasocitinib In Dry Eye SubjectsWithdrawnNCT01226680Phase 2
- Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly VolunteersCompletedNCT01225224Phase 1
- A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.TerminatedNCT01219543Phase 1
- Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy VolunteersCompletedNCT01204112Phase 1
- A Study to Evaluate the Drug Interaction of ASP015K and TacrolimusCompletedNCT01190670Phase 1
- Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy VolunteersCompletedNCT01185184Phase 1
- A Study to Assess Drug Interaction of ASP015K and MidazolamCompletedNCT01182077Phase 1
- First-in-Human Single Ascending and Multiple Dose of GLPG0634CompletedNCT01179581Phase 1
- INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseCompletedNCT01164163Phase 1
- A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet FormCompletedNCT01143805Phase 1
- A Study in Myeloproliferative DisordersCompletedNCT01134120Phase 1
- Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid TumoursTerminatedNCT01112397Phase 1
- CP-690,550 Pharmacokinetics In Healthy Chinese SubjectsCompletedNCT01101919Phase 1
- A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisCompletedNCT01096862Phase 2
- A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product TestersCompletedNCT01023100Phase 1
- A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT00969813Phase 1
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT00935987Phase 1/2
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic MyelofibrosisCompletedNCT00745550Phase 1/2
- A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT00741871Phase 1
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With MyelofibrosisCompletedNCT00631462Phase 1
- A Phase 1 Study of XL019 in Adults With Polycythemia VeraTerminatedNCT00595829Phase 1
- Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant PatientsWithdrawnNCT00556257Phase 2
- A Safety Study of XL019 in Adults With MyelofibrosisTerminatedNCT00522574Phase 1
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeActive, not recruitingNCT00044304Phase 2